Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
1.000
0.00 (0.00%)
Nov 21, 2024, 1:29 PM EST - Market open
Nektar Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 93.14 | 90.12 | 92.06 | 101.91 | 152.92 | 114.62 | Upgrade
|
| Revenue Growth (YoY) | 5.53% | -2.10% | -9.67% | -33.36% | 33.41% | -90.40% | Upgrade
|
| Cost of Revenue | 29.99 | 33.77 | 21.64 | 24.9 | 19.48 | 21.37 | Upgrade
|
| Gross Profit | 63.15 | 56.35 | 70.42 | 77.01 | 133.44 | 93.24 | Upgrade
|
| Selling, General & Admin | 76.94 | 77.42 | 92.33 | 122.84 | 104.68 | 98.71 | Upgrade
|
| Research & Development | 122.11 | 114.16 | 218.32 | 400.27 | 408.68 | 434.57 | Upgrade
|
| Operating Expenses | 199.04 | 191.58 | 310.66 | 523.11 | 513.36 | 533.28 | Upgrade
|
| Operating Income | -135.9 | -135.23 | -240.24 | -446.1 | -379.92 | -440.04 | Upgrade
|
| Interest Expense | -24.83 | -25.33 | -28.91 | -47.31 | -37.12 | -46.35 | Upgrade
|
| Interest & Investment Income | 16.18 | 19.01 | 6.78 | 2.73 | 18.28 | 46.34 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.5 | -1.15 | 33.31 | -8.19 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -146.05 | -142.7 | -229.05 | -498.87 | -398.76 | -440.05 | Upgrade
|
| Merger & Restructuring Charges | -17.16 | -51.96 | -135.93 | - | - | - | Upgrade
|
| Impairment of Goodwill | - | -76.5 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -5.1 | -5.1 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -24.41 | -45.19 | - | Upgrade
|
| Pretax Income | -168.31 | -276.26 | -364.98 | -523.28 | -443.95 | -440.05 | Upgrade
|
| Income Tax Expense | -0.01 | -0.2 | 3.22 | 0.56 | 0.49 | 0.61 | Upgrade
|
| Net Income | -168.3 | -276.06 | -368.2 | -523.84 | -444.44 | -440.67 | Upgrade
|
| Net Income to Common | -168.3 | -276.06 | -368.2 | -523.84 | -444.44 | -440.67 | Upgrade
|
| Shares Outstanding (Basic) | 201 | 190 | 187 | 183 | 179 | 175 | Upgrade
|
| Shares Outstanding (Diluted) | 201 | 190 | 187 | 183 | 179 | 175 | Upgrade
|
| Shares Change (YoY) | 6.17% | 1.53% | 2.09% | 2.64% | 2.05% | -2.85% | Upgrade
|
| EPS (Basic) | -0.84 | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | Upgrade
|
| EPS (Diluted) | -0.84 | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | Upgrade
|
| Free Cash Flow | -177.82 | -193.47 | -309.68 | -427.65 | -320.55 | -354.97 | Upgrade
|
| Free Cash Flow Per Share | -0.88 | -1.02 | -1.65 | -2.33 | -1.79 | -2.03 | Upgrade
|
| Gross Margin | 67.80% | 62.53% | 76.50% | 75.57% | 87.26% | 81.35% | Upgrade
|
| Operating Margin | -145.91% | -150.05% | -260.97% | -437.76% | -248.45% | -383.92% | Upgrade
|
| Profit Margin | -180.70% | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | Upgrade
|
| Free Cash Flow Margin | -190.92% | -214.68% | -336.41% | -419.65% | -209.62% | -309.70% | Upgrade
|
| EBITDA | -130.19 | -127.41 | -227.21 | -431.96 | -365.74 | -426.88 | Upgrade
|
| EBITDA Margin | -139.78% | -141.38% | -246.82% | - | -239.18% | - | Upgrade
|
| D&A For EBITDA | 5.71 | 7.82 | 13.03 | 14.15 | 14.18 | 13.16 | Upgrade
|
| EBIT | -135.9 | -135.23 | -240.24 | -446.1 | -379.92 | -440.04 | Upgrade
|
| EBIT Margin | -145.91% | -150.05% | -260.97% | - | -248.45% | - | Upgrade
|
| Revenue as Reported | 93.14 | 90.12 | 92.06 | 101.91 | 152.92 | 114.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.